Your institution may have access to this item. Find your institution then sign in to continue.
Title
Risperdal.
Abstract
The article features Risperdal (Risperidone) drug from Janssen Pharmaceutica Products LP for the treatment of schizophrenia in adolescent patients aged 13 to 17 years and for the short-term treatment of bipolar I disorder in pediatric and adolescent patients aged 10 to 17 years. The evaluation of its effectiveness was discussed, as well as the drug's safety and administration.